Successful Treatment of Primary Aldosteronism With Partial Adrenalectomy, Facilitated By The Use of ¹¹C-Metomidate PET/CT

W A Bashari¹, A Powlson¹, O Kolouri¹, D Quill⁴, MJ Brown², HK Cheow⁵, C Dennedy³, M Gurnell¹ ¹Institute of Metabolic Science & ²Department of Clinical Pharmacology, University of Cambridge & Addenbrooke's Hospital, Cambridge, UK ³Department of Endocrinology & ⁴Department of Surgery, University Hospital Galway, Galway, Ireland ⁵Department of Radiology, Addenbrooke's Hospital, Cambridge, UK



Galway University Hospitals Ospidéil na h-Ollscoile Gaillimh UNIVERSITY HOSPITAL GALWAY MERLIN PARK UNIVERSITY HOSPITAL



Background

Primary aldosteronism (PA) is estimated to be responsible for 5-10% of all cases of hypertension (HTN)^{1.} The current gold standard test for determining lateralisation in PA is adrenal vein sampling (AVS). ¹¹C-Metomidate PET/CT (MTO-PET) has recently emerged as a potential non-invasive alternative to AVS². As ¹¹C-Metomidate is concentrated within 'hyper-functioning' nodules, MTO-PET potentially not only identifies the side, but the exact site of aldosterone hypersecretion, thus raising the possibility of more targeted surgical intervention.

¹¹C-Metomidate PET/CT:



Case Report

A 45-year-old man was noted to have HTN and hypokalaemia following a myocardial infarction. He required four anti-hypertensive agents to achieve BP control. His plasma aldosterone was elevated with a suppressed plasma renin (off interfering medications), and aldosterone did not adequately decrease following saline suppression, confirming the diagnosis of PA. Adrenal CT and MRI did not convincingly demonstrate a lesion. He underwent AVS, but the result was inconclusive (right adrenal vein not cannulated). MTO-PET revealed focally increased tracer uptake in a sub-centimetre nodule in the left adrenal gland.

Investigations

ARR screening:

| Renin | <2 | mU/L |
|-------------|-----|--------|
| Aldosterone | 932 | pmol/L |





Saline infusion test:

| Time | Aldosterone | Renin | Cortisol |
|------|-------------|-------|----------|
| 0h | 934 | <0.2 | 586 |
| +4h | 584 | <0.2 | 213 |

Adrenal Vein Sampling:

| Site | Cortisol | Aldosterone | Aldo:Cort |
|---------------|----------|-------------|-----------|
| Periphery | 522 | 1028 | 1.97 |
| Left Adrenal | 816 | 37763 | 46.27 |
| Right Adrenal | 487 | 969 | 1.99 |

CT Adrenal:







Treatment and outcome

The patient underwent a posterior retroperitoneoscopic procedure, during which the nodule and lateral limb of the left adrenal were selectively removed, leaving the rest of the gland in situ. Histology confirmed the presence of a small Conn's adenoma. The patient is normotensive post-surgery (BP 110/74 mmHg), on no antihypertensive medications, with normal biochemistry.





| | Pre-op | Day 2 | Month 3 | |
|-------------|--------|-------|---------|--------|
| Renin | <2 | 63.8 | 30.9 | mU/L |
| Aldosterone | 932 | <102 | 352 | pmol/L |

Conclusion

This case highlights the ability of MTO-PET to not only lateralise, but actually localise the site of aldosterone hypersecretion, and thereby guide selective removal of a Conn's adenoma with sparing of the adjacent normal adrenal gland.

References: 1. Funder et al. *JCEM*, 2008 2. Burton et al. *JCEM*. 2012